EC
OLMA icon

EntryPoint Capital’s Olema Pharmaceuticals OLMA Stock Holding History

EntryPoint Capital’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-69,526
Closed -$405K – 877
2024
Q4 		$405K Buy
69,526
+34,982
+101% +$349K 0.17% 198
2024
Q3 		$412K Buy
+34,544
New +$442K 0.23% 112
2024
Q2 		– Sell
-14,530
Closed -$164K – 1418
2024
Q1 		$164K Buy
14,530
+13,146
+950% +$170K 0.15% 179
2023
Q4 		$19.4K Buy
+1,384
New +$18.6K 0.02% 1055

Other funds holding OLMA

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LMC
Lightspeed Management Company Menlo Park, California $988M AUM 7.5% 1-Year Est. Return

EntryPoint Capital's OLMA Position: Q1 2025 in Review

EntryPoint Capital sold out of Olema Pharmaceuticals (OLMA) in Q1 2025, closing a stake of 69,526 shares — an estimated $405K sold.

EntryPoint Capital first reported a position in OLMA in Q4 2023 and held it in 4 quarters. The position peaked at $412K in Q3 2024. 133 funds tracked by Wall St. Rank hold OLMA as of Q1 2025.

  • EntryPoint Capital reported no remaining Olema Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • EntryPoint Capital sold 69,526 Olema Pharmaceuticals shares in Q1 2025, an estimated $405K.
  • EntryPoint Capital first reported a position in Olema Pharmaceuticals in Q4 2023 and held it in 4 quarters.
  • EntryPoint Capital's Olema Pharmaceuticals position peaked at $412K in Q3 2024.
  • 133 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q1 2025.

Based on EntryPoint Capital's 13F filing for Q1 2025, filed 14 May 2025.